Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1948 1
1950 2
1951 3
1952 3
1953 3
1954 5
1955 8
1956 8
1957 11
1958 9
1959 18
1960 10
1961 9
1962 9
1963 12
1964 9
1965 10
1966 8
1967 4
1968 9
1969 7
1970 8
1971 4
1972 3
1973 7
1974 4
1975 8
1976 17
1977 17
1978 20
1979 10
1980 13
1981 12
1982 12
1983 26
1984 24
1985 23
1986 32
1987 22
1988 29
1989 35
1990 31
1991 28
1992 30
1993 33
1994 25
1995 23
1996 35
1997 33
1998 41
1999 28
2000 35
2001 35
2002 25
2003 27
2004 29
2005 39
2006 36
2007 37
2008 30
2009 23
2010 33
2011 34
2012 43
2013 54
2014 57
2015 77
2016 70
2017 83
2018 84
2019 94
2020 84
2021 35
Text availability
Article attribute
Article type
Publication date

Search Results

1,740 results
Results by year
Filters applied: . Clear all
Page 1
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.
Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK. Subbiah V, et al. Among authors: wolf b. Cancer Discov. 2018 Jul;8(7):836-849. doi: 10.1158/2159-8290.CD-18-0338. Epub 2018 Apr 15. Cancer Discov. 2018. PMID: 29657135 Free article.
Environment dominates over host genetics in shaping human gut microbiota.
Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, Costea PI, Godneva A, Kalka IN, Bar N, Shilo S, Lador D, Vila AV, Zmora N, Pevsner-Fischer M, Israeli D, Kosower N, Malka G, Wolf BC, Avnit-Sagi T, Lotan-Pompan M, Weinberger A, Halpern Z, Carmi S, Fu J, Wijmenga C, Zhernakova A, Elinav E, Segal E. Rothschild D, et al. Among authors: wolf bc. Nature. 2018 Mar 8;555(7695):210-215. doi: 10.1038/nature25973. Epub 2018 Feb 28. Nature. 2018. PMID: 29489753
Urinary tract infections.
Kumar S, Dave A, Wolf B, Lerma EV. Kumar S, et al. Among authors: wolf b. Dis Mon. 2015 Feb;61(2):45-59. doi: 10.1016/j.disamonth.2014.12.002. Dis Mon. 2015. PMID: 25732782 Review. No abstract available.
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.
Lisberg A, Cummings A, Goldman JW, Bornazyan K, Reese N, Wang T, Coluzzi P, Ledezma B, Mendenhall M, Hunt J, Wolf B, Jones B, Madrigal J, Horton J, Spiegel M, Carroll J, Gukasyan J, Williams T, Sauer L, Wells C, Hardy A, Linares P, Lim C, Ma L, Adame C, Garon EB. Lisberg A, et al. Among authors: wolf b. J Thorac Oncol. 2018 Aug;13(8):1138-1145. doi: 10.1016/j.jtho.2018.03.035. Epub 2018 Jun 1. J Thorac Oncol. 2018. PMID: 29874546 Free PMC article. Clinical Trial.
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.
Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, Marcoux N, Banwait MK, Digumarthy SR, Su W, Yoda S, Riley AK, Nangia V, Lin JJ, Nagy RJ, Lanman RB, Dias-Santagata D, Mino-Kenudson M, Iafrate AJ, Heist RS, Shaw AT, Evans EK, Clifford C, Ou SI, Wolf B, Hata AN, Sequist LV. Piotrowska Z, et al. Among authors: wolf b. Cancer Discov. 2018 Dec;8(12):1529-1539. doi: 10.1158/2159-8290.CD-18-1022. Epub 2018 Sep 26. Cancer Discov. 2018. PMID: 30257958 Free PMC article.
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.
Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK. Kim RD, et al. Among authors: wolf bb. Cancer Discov. 2019 Dec;9(12):1696-1707. doi: 10.1158/2159-8290.CD-19-0555. Epub 2019 Oct 1. Cancer Discov. 2019. PMID: 31575541 Free article. Clinical Trial.
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
Hatlen MA, Schmidt-Kittler O, Sherwin CA, Rozsahegyi E, Rubin N, Sheets MP, Kim JL, Miduturu C, Bifulco N, Brooijmans N, Shi H, Guzi T, Boral A, Lengauer C, Dorsch M, Kim RD, Kang YK, Wolf BB, Hoeflich KP. Hatlen MA, et al. Among authors: wolf bb. Cancer Discov. 2019 Dec;9(12):1686-1695. doi: 10.1158/2159-8290.CD-19-0367. Epub 2019 Oct 1. Cancer Discov. 2019. PMID: 31575540 Free article.
Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.
Eskiocak U, Guzman W, Wolf B, Cummings C, Milling L, Wu HJ, Ophir M, Lambden C, Bakhru P, Gilmore DC, Ottinger S, Liu L, McConaughy WK, He SQ, Wang C, Leung CL, Lajoie J, Carson WF 4th, Zizlsperger N, Schmidt MM, Anderson AC, Bobrowicz P, Schuetz TJ, Tighe R. Eskiocak U, et al. Among authors: wolf b. JCI Insight. 2020 Mar 12;5(5):e133647. doi: 10.1172/jci.insight.133647. JCI Insight. 2020. PMID: 32161196 Free PMC article.
1,740 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page